Identification

Name
Carbinoxamine
Accession Number
DB00748  (APRD00765)
Type
Small Molecule
Groups
Approved
Description

Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under 2 years of age), which can potentially cause serious health risks.

Structure
Thumb
Synonyms
  • (+-)-Carbinoxamine
  • {2-[(4-chloro-phenyl)-pyridin-2-yl-methoxy]-ethyl}-dimethyl-amine
  • 2-(P-chloro-alpha-(2-(dimethylamino)Ethoxy)benzyl)pyridine
  • Carbinoxamin
  • Carbinoxamina
  • Carbinoxamine
  • Carbinoxamine base
  • Carbinoxaminum
  • Paracarbinoxamine
Product Ingredients
IngredientUNIICASInChI Key
Carbinoxamine Maleate02O55696WH3505-38-2GVNWHCVWDRNXAZ-BTJKTKAUSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Karbinal ERSuspension, extended release4 mg/5mLOralAvadel Pharmaceuticals (Usa), Inc.2014-01-03Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ArbinoxaTablet4 mg/1OralHawthorn Pharmaceuticals, Inc.2010-08-232017-10-17Us
ArbinoxaSolution.8 mg/mLOralHawthorn Pharmaceuticals, Inc.2011-04-012016-12-08Us
Carbinoxamine MaleateTablet4 mg/1OralBiocomp Pharma, Inc.2011-05-27Not applicableUs
Carbinoxamine MaleateTablet4 mg/1OralCypress Pharmaceuticals, Inc.2010-08-232017-10-17Us
Carbinoxamine MaleateSolution4 mg/5mLOralBoca Pharmacal, Inc.2008-02-26Not applicableUs
Carbinoxamine MaleateTablet4 mg/1OralBreckenridge Pharmaceutical, Inc.2012-12-10Not applicableUs
Carbinoxamine MaleateTablet4 mg/1OralMikart, Inc.2003-03-19Not applicableUs
Carbinoxamine MaleateTablet6 mg/1OralMikart, Inc.2016-05-31Not applicableUs
Carbinoxamine MaleateSyrup4 mg/5mLOralBreckenridge Pharmaceutical, Inc.2012-12-10Not applicableUs
Carbinoxamine MaleateSyrup4 mg/5mLOralMikart, Inc.2003-04-25Not applicableUs
International/Other Brands
Allergefon (SERP) / Clistin / Histin (Kenyaku) / Karbinal / Rotoxamine / Satinmin (Shou Chan)
Categories
UNII
982A7M02H5
CAS number
486-16-8
Weight
Average: 290.788
Monoisotopic: 290.118590947
Chemical Formula
C16H19ClN2O
InChI Key
OJFSXZCBGQGRNV-UHFFFAOYSA-N
InChI
InChI=1S/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3
IUPAC Name
{2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]ethyl}dimethylamine
SMILES
CN(C)CCOC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1

Pharmacology

Indication

For symptomatic relief of seasonal and perennial allergic rhinitis and vasomotor rhinitis, as well as allergic conjunctivitis caused by foods and inhaled allergens. Also for the relief of allergic reactions to blood or plasma, and the symptomatic management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema.

Structured Indications
Pharmacodynamics

Carbinoxamine is a first generation antihistamine of the ethanolamine class. Ethanolamine antihistamines have significant antimuscarinic activity and produce marked sedation in most patients. In addition to the usual allergic symptoms, the drug also treats irritant cough and nausea, vomiting, and vertigo associated with motion sickness. It also is used commonly to treat drug-induced extrapyramidal symptoms as well as to treat mild cases of Parkinson's disease. Rather than preventing the release of histamine, as do cromolyn and nedocromil, carbinoxamine competes with free histamine for binding at HA-receptor sites. Carbinoxamine competitively antagonizes the effects of histamine on HA-receptors in the GI tract, uterus, large blood vessels, and bronchial muscle. Ethanolamine derivatives have greater anticholinergic activity than do other antihistamines, which probably accounts for the antidyskinetic action of carbinoxamine.

Mechanism of action

Carbinoxamine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. Carbinoxamine's anticholinergic action appears to be due to a central antimuscarinic effect, which also may be responsible for its antiemetic effects, although the exact mechanism is unknown.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

10 to 20 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Carbinoxamine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Carbinoxamine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Carbinoxamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Carbinoxamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Carbinoxamine.Experimental
AbirateroneThe serum concentration of Carbinoxamine can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Carbinoxamine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Carbinoxamine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Carbinoxamine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Carbinoxamine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Carbinoxamine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Carbinoxamine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Carbinoxamine.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Carbinoxamine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Carbinoxamine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Carbinoxamine.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Carbinoxamine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Carbinoxamine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Carbinoxamine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Carbinoxamine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Carbinoxamine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Carbinoxamine.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Carbinoxamine.Approved, Illicit
AprepitantThe serum concentration of Carbinoxamine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Carbinoxamine.Approved, Investigational
ArmodafinilThe metabolism of Carbinoxamine can be decreased when combined with Armodafinil.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Carbinoxamine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Carbinoxamine.Approved
AtazanavirThe metabolism of Carbinoxamine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Carbinoxamine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Carbinoxamine.Investigational, Vet Approved
AzelastineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Carbinoxamine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Carbinoxamine.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Carbinoxamine.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Carbinoxamine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Carbinoxamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Carbinoxamine.Approved
Benzylpenicilloyl PolylysineCarbinoxamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Carbinoxamine.Approved
BoceprevirThe metabolism of Carbinoxamine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Carbinoxamine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Carbinoxamine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Carbinoxamine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Carbinoxamine.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Carbinoxamine.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Carbinoxamine.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Carbinoxamine.Approved, Investigational
BuprenorphineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Carbinoxamine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Carbinoxamine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Carbinoxamine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Carbinoxamine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Carbinoxamine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Carbinoxamine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Carbinoxamine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Carbinoxamine.Investigational
CapecitabineThe metabolism of Carbinoxamine can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Carbinoxamine can be increased when combined with Carbamazepine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Carbinoxamine.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Carbinoxamine.Approved
CelecoxibThe metabolism of Carbinoxamine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Carbinoxamine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Carbinoxamine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Carbinoxamine.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Carbinoxamine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Carbinoxamine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Carbinoxamine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Carbinoxamine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Carbinoxamine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Carbinoxamine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Carbinoxamine.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Carbinoxamine.Approved
CholecalciferolThe metabolism of Carbinoxamine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Carbinoxamine can be decreased when combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Carbinoxamine.Approved, Vet Approved
CitalopramThe metabolism of Carbinoxamine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Carbinoxamine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Carbinoxamine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Carbinoxamine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Carbinoxamine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Carbinoxamine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Carbinoxamine.Experimental
ClopidogrelThe metabolism of Carbinoxamine can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Carbinoxamine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Carbinoxamine.Experimental
ClotrimazoleThe metabolism of Carbinoxamine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Carbinoxamine.Approved
CobicistatThe metabolism of Carbinoxamine can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Carbinoxamine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Carbinoxamine.Approved, Illicit
ConivaptanThe serum concentration of Carbinoxamine can be increased when it is combined with Conivaptan.Approved, Investigational
CrisaboroleThe metabolism of Carbinoxamine can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Carbinoxamine can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carbinoxamine.Approved
CyclosporineThe metabolism of Carbinoxamine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Carbinoxamine.Approved
Cyproterone acetateThe serum concentration of Carbinoxamine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Carbinoxamine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Carbinoxamine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Carbinoxamine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Carbinoxamine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Carbinoxamine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Carbinoxamine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Carbinoxamine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Carbinoxamine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Carbinoxamine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Carbinoxamine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Carbinoxamine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Carbinoxamine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Carbinoxamine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Carbinoxamine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Carbinoxamine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Carbinoxamine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Carbinoxamine.Experimental
DiethylpropionDiethylpropion may decrease the sedative activities of Carbinoxamine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Carbinoxamine.Approved, Illicit
DihydroergotamineThe metabolism of Carbinoxamine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Carbinoxamine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Carbinoxamine.Experimental, Illicit
DiltiazemThe metabolism of Carbinoxamine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Carbinoxamine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Carbinoxamine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Carbinoxamine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Carbinoxamine.Vet Approved
DosulepinThe metabolism of Carbinoxamine can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Doxepin.Approved
DoxorubicinThe metabolism of Carbinoxamine can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Carbinoxamine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Carbinoxamine.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved, Illicit
DronedaroneThe metabolism of Carbinoxamine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Carbinoxamine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Carbinoxamine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Carbinoxamine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Carbinoxamine.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Carbinoxamine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Carbinoxamine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Carbinoxamine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Carbinoxamine.Approved, Investigational
EnzalutamideThe serum concentration of Carbinoxamine can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Carbinoxamine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Carbinoxamine can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Carbinoxamine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Carbinoxamine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Carbinoxamine.Approved
EthanolCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carbinoxamine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Carbinoxamine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Carbinoxamine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Carbinoxamine.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Carbinoxamine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Carbinoxamine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Carbinoxamine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Carbinoxamine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Carbinoxamine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Carbinoxamine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Carbinoxamine.Illicit, Vet Approved
EtravirineThe metabolism of Carbinoxamine can be decreased when combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Felbamate.Approved
FelodipineThe metabolism of Carbinoxamine can be decreased when combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Carbinoxamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Carbinoxamine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Carbinoxamine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Flibanserin.Approved
FloxuridineThe metabolism of Carbinoxamine can be decreased when combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Carbinoxamine.Experimental
FluconazoleThe metabolism of Carbinoxamine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Carbinoxamine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Carbinoxamine.Approved, Illicit
FluorouracilThe metabolism of Carbinoxamine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Carbinoxamine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Carbinoxamine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Carbinoxamine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Carbinoxamine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Carbinoxamine.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Carbinoxamine.Approved
FluvastatinThe metabolism of Carbinoxamine can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Carbinoxamine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Carbinoxamine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Carbinoxamine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Carbinoxamine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Carbinoxamine.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Carbinoxamine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Carbinoxamine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Carbinoxamine.Approved, Illicit, Investigational
GemfibrozilThe metabolism of Carbinoxamine can be decreased when combined with Gemfibrozil.Approved
GepefrineGepefrine may decrease the sedative activities of Carbinoxamine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Carbinoxamine.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Carbinoxamine.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Carbinoxamine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Carbinoxamine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Carbinoxamine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Carbinoxamine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Carbinoxamine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Carbinoxamine.Approved, Investigational
HydrocodoneCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Carbinoxamine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Carbinoxamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved
IdelalisibThe serum concentration of Carbinoxamine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Iloperidone.Approved
ImatinibThe metabolism of Carbinoxamine can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Carbinoxamine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Carbinoxamine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Carbinoxamine.Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Carbinoxamine.Approved
IrbesartanThe metabolism of Carbinoxamine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Carbinoxamine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Carbinoxamine.Approved, Vet Approved
IsoniazidThe metabolism of Carbinoxamine can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Carbinoxamine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Carbinoxamine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Carbinoxamine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Carbinoxamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Carbinoxamine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Carbinoxamine.Approved, Investigational
KetoconazoleThe metabolism of Carbinoxamine can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Carbinoxamine.Approved, Investigational
LapatinibThe metabolism of Carbinoxamine can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Carbinoxamine can be decreased when combined with Leflunomide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Carbinoxamine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Carbinoxamine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Carbinoxamine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Carbinoxamine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Carbinoxamine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Carbinoxamine.Approved
LobeglitazoneThe metabolism of Carbinoxamine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Carbinoxamine.Illicit
LopinavirThe metabolism of Carbinoxamine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Carbinoxamine.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Carbinoxamine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Carbinoxamine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Carbinoxamine.Approved
LosartanThe metabolism of Carbinoxamine can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Carbinoxamine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Carbinoxamine.Approved
LuliconazoleThe serum concentration of Carbinoxamine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Carbinoxamine can be increased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Carbinoxamine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved, Vet Approved
ManidipineThe metabolism of Carbinoxamine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Carbinoxamine.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Carbinoxamine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Carbinoxamine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Carbinoxamine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Carbinoxamine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Carbinoxamine.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Carbinoxamine.Investigational
MephentermineMephentermine may decrease the sedative activities of Carbinoxamine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Carbinoxamine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Carbinoxamine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Carbinoxamine.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Carbinoxamine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Carbinoxamine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Carbinoxamine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Carbinoxamine.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Carbinoxamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Carbinoxamine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Carbinoxamine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Carbinoxamine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Carbinoxamine.Approved
MethotrimeprazineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Carbinoxamine.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Carbinoxamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Carbinoxamine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Carbinoxamine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Carbinoxamine.Approved, Investigational
MetyrosineCarbinoxamine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Carbinoxamine.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative activities of Carbinoxamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Carbinoxamine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Carbinoxamine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved, Investigational
MirtazapineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Carbinoxamine can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may decrease the sedative activities of Carbinoxamine.Experimental, Illicit
MoclobemideThe metabolism of Carbinoxamine can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Carbinoxamine can be decreased when combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Carbinoxamine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Carbinoxamine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Carbinoxamine.Approved
NefazodoneThe metabolism of Carbinoxamine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Carbinoxamine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Carbinoxamine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Carbinoxamine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Carbinoxamine can be decreased when combined with Nicardipine.Approved
NicotineThe metabolism of Carbinoxamine can be decreased when combined with Nicotine.Approved
NilotinibThe metabolism of Carbinoxamine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Carbinoxamine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Carbinoxamine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Carbinoxamine.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Carbinoxamine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Carbinoxamine.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Carbinoxamine.Approved, Investigational
OlaparibThe metabolism of Carbinoxamine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Carbinoxamine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Carbinoxamine.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Carbinoxamine.Approved, Illicit
OrphenadrineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Carbinoxamine.Investigational
OsimertinibThe serum concentration of Carbinoxamine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Carbinoxamine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Carbinoxamine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Carbinoxamine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Carbinoxamine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Carbinoxamine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Carbinoxamine.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Carbinoxamine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Carbinoxamine.Approved
PantoprazoleThe metabolism of Carbinoxamine can be decreased when combined with Pantoprazole.Approved
ParaldehydeCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe metabolism of Carbinoxamine can be decreased when combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Carbinoxamine.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Carbinoxamine.Approved, Vet Approved
PentobarbitalThe metabolism of Carbinoxamine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Carbinoxamine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Carbinoxamine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Carbinoxamine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Carbinoxamine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Carbinoxamine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Carbinoxamine.Experimental
PhenobarbitalThe metabolism of Carbinoxamine can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Carbinoxamine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Carbinoxamine.Approved
PhenterminePhentermine may decrease the sedative activities of Carbinoxamine.Approved, Illicit
PhenytoinThe metabolism of Carbinoxamine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Carbinoxamine.Approved
PioglitazoneThe metabolism of Carbinoxamine can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Carbinoxamine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Carbinoxamine.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Carbinoxamine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleCarbinoxamine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Carbinoxamine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Carbinoxamine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Carbinoxamine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Carbinoxamine.Approved
PrimidoneThe metabolism of Carbinoxamine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Carbinoxamine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Carbinoxamine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Carbinoxamine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Carbinoxamine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Carbinoxamine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Carbinoxamine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Carbinoxamine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Carbinoxamine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Carbinoxamine.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Carbinoxamine.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Carbinoxamine.Approved
PyrimethamineThe metabolism of Carbinoxamine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Carbinoxamine can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carbinoxamine.Approved
QuinineThe metabolism of Carbinoxamine can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Carbinoxamine.Experimental
RabeprazoleThe metabolism of Carbinoxamine can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Carbinoxamine.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Carbinoxamine can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Carbinoxamine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Carbinoxamine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Carbinoxamine.Approved, Investigational
RifabutinThe metabolism of Carbinoxamine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Carbinoxamine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Carbinoxamine can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Carbinoxamine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Carbinoxamine.Investigational
RitobegronRitobegron may decrease the sedative activities of Carbinoxamine.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Carbinoxamine.Vet Approved
RopiniroleCarbinoxamine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Carbinoxamine.Approved
RosiglitazoneThe metabolism of Carbinoxamine can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotineCarbinoxamine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Carbinoxamine.Approved
SaquinavirThe metabolism of Carbinoxamine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Carbinoxamine.Approved
SecobarbitalThe metabolism of Carbinoxamine can be increased when combined with Secobarbital.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Carbinoxamine.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Carbinoxamine.Approved, Investigational, Withdrawn
SertralineThe metabolism of Carbinoxamine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Carbinoxamine.Approved, Vet Approved
SildenafilThe metabolism of Carbinoxamine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Carbinoxamine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Carbinoxamine can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved
SorafenibThe metabolism of Carbinoxamine can be decreased when combined with Sorafenib.Approved, Investigational
St. John's WortThe serum concentration of Carbinoxamine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Carbinoxamine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Carbinoxamine.Approved, Investigational
SulfadiazineThe metabolism of Carbinoxamine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Carbinoxamine can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Carbinoxamine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Carbinoxamine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Carbinoxamine.Experimental
SuvorexantCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenThe metabolism of Carbinoxamine can be decreased when combined with Tamoxifen.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Carbinoxamine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Carbinoxamine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Carbinoxamine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Carbinoxamine.Approved
TeriflunomideThe metabolism of Carbinoxamine can be decreased when combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Carbinoxamine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Carbinoxamine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Carbinoxamine.Investigational
ThalidomideCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Carbinoxamine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Carbinoxamine.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Carbinoxamine.Approved, Withdrawn
ThiotepaThe metabolism of Carbinoxamine can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Carbinoxamine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Carbinoxamine.Approved, Investigational
TicagrelorThe metabolism of Carbinoxamine can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Carbinoxamine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Carbinoxamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Carbinoxamine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Carbinoxamine.Approved
TocilizumabThe serum concentration of Carbinoxamine can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Carbinoxamine can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Carbinoxamine.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Carbinoxamine.Approved
TopiroxostatThe metabolism of Carbinoxamine can be decreased when combined with Topiroxostat.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Carbinoxamine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Carbinoxamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Carbinoxamine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Carbinoxamine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Carbinoxamine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Carbinoxamine.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Carbinoxamine.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Carbinoxamine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Carbinoxamine.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Carbinoxamine.Approved, Vet Approved
TrimethoprimThe metabolism of Carbinoxamine can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Carbinoxamine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Carbinoxamine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Carbinoxamine.Approved, Investigational
ValsartanThe metabolism of Carbinoxamine can be decreased when combined with Valsartan.Approved, Investigational
VenlafaxineThe metabolism of Carbinoxamine can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Carbinoxamine.Experimental
VerapamilThe metabolism of Carbinoxamine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Carbinoxamine.Experimental
VoriconazoleThe metabolism of Carbinoxamine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Carbinoxamine.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Carbinoxamine.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Carbinoxamine.Vet Approved
ZafirlukastThe metabolism of Carbinoxamine can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Carbinoxamine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Carbinoxamine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Carbinoxamine.Vet Approved
ZolpidemCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Carbinoxamine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Carbinoxamine.Approved, Investigational
ZucapsaicinThe metabolism of Carbinoxamine can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Carbinoxamine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Tilford. C.H. and Shelton, R.S.; U.S. Patent 2,606,195;August 5,1952; assigned to The Wm.S. Merrell Company. Swain, A.P.; U.S. Patent 2800,485; July 23,1957; assigned to McNeil Laboratories, Inc.

General References
  1. BEALE HD, RAWLING FF, FIGLEY KD: Clistin maleate; a clinical appraisal of a new antihistaminic. J Allergy. 1954 Nov;25(6):521-4. [PubMed:13211145]
External Links
Human Metabolome Database
HMDB14886
KEGG Compound
C06871
PubChem Compound
2564
PubChem Substance
46506787
ChemSpider
2466
BindingDB
81464
ChEBI
3398
ChEMBL
CHEMBL864
Therapeutic Targets Database
DAP001069
PharmGKB
PA164746898
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Carbinoxamine
ATC Codes
R06AA08 — Carbinoxamine
MSDS
Download (74.6 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Mcneil pharmaceutical co div mcneilab inc
  • Boca pharmacal inc
  • Cypress pharmaceutical inc
  • Mikart inc
  • Invagen pharmaceuticals inc
  • Ortho mcneil pharmaceutical inc
Packagers
Dosage forms
FormRouteStrength
SolutionOral.8 mg/mL
SolutionOral4 mg/5mL
SyrupOral4 mg/5mL
TabletOral4 mg/1
TabletOral6 mg/1
Suspension, extended releaseOral4 mg/5mL
Prices
Unit descriptionCostUnit
Palgic 4 mg tablet0.87USD tablet
Carbinoxamine maleate 4 mg tablet0.65USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8062667No2009-03-292029-03-29Us
US9522191No2007-06-152027-06-15Us

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)< 25 °CPhysProp
boiling point (°C)160 °C at 1.00E-01 mm HgPhysProp
logP2.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.228 mg/mLALOGPS
logP3.03ALOGPS
logP3.27ChemAxon
logS-3.1ALOGPS
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area25.36 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity82.13 m3·mol-1ChemAxon
Polarizability31.7 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9787
Blood Brain Barrier+0.955
Caco-2 permeable+0.7503
P-glycoprotein substrateSubstrate0.6804
P-glycoprotein inhibitor INon-inhibitor0.5997
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterInhibitor0.7956
CYP450 2C9 substrateNon-substrate0.8203
CYP450 2D6 substrateSubstrate0.5558
CYP450 3A4 substrateSubstrate0.6473
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8452
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8403
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5557
Ames testNon AMES toxic0.8751
CarcinogenicityNon-carcinogens0.9182
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9003 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7085
hERG inhibition (predictor II)Inhibitor0.6835
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0ab9-9000000000-a413c068c7a879eb2068
Mass Spectrum (Electron Ionization)MSsplash10-0ab9-9200000000-c3abf61d5cdaa81de77d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0uxr-0490000000-9ece1371a4992f21aa52

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzylethers. These are aromatic ethers with the general formula ROCR' (R = alkyl, aryl; R'=benzene).
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzylethers
Direct Parent
Benzylethers
Alternative Parents
Chlorobenzenes / Pyridines and derivatives / Aryl chlorides / Heteroaromatic compounds / Trialkylamines / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
Benzylether / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Pyridine / Heteroaromatic compound / Tertiary aliphatic amine / Tertiary amine / Dialkyl ether
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
tertiary amino compound, pyridines, monochlorobenzenes (CHEBI:3398)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Oishi R, Shishido S, Yamori M, Saeki K: Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):140-4. [PubMed:7513381]
  2. Ramadan AA, Mandil H: Spectrophotometric determination of carbinoxamine maleate in pharmaceutical formulations by ternary complex formation with Cu(II) and eosin. Anal Biochem. 2006 Jun 1;353(1):133-7. Epub 2006 Mar 9. [PubMed:16574052]
  3. Darby WJ: Nutrition, food needs and technologic priorities: the World Food Conference. Nutr Rev. 1975 Aug;33(8):225-34. [PubMed:1143714]
  4. Yang J, Dudley GB: [1,2]-Anionic rearrangement of 2-benzyloxypyridine and related pyridyl ethers. J Org Chem. 2009 Oct 16;74(20):7998-8000. doi: 10.1021/jo901707x. [PubMed:19761204]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:42